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Background: Pneumonia is a leading cause of death in children under-five. Epidemiology in our 
province at regional level has not been described since 2004, when HAART was rolled out and 
pneumococcal conjugate vaccination (PCV) was introduced. 
Objectives: Describe the demographic profile, disease severity, risks for transfer and mortality 
and the management of children >2 months, admitted with CAP over a one year period. 
Methods: Retrospective descriptive study of every second patient (>2 months to 13 years) 
admitted to Somerset Hospital in 2012 with the diagnosis of CAP. Demographic, clinical and 
outcome data were extracted from hospital records and analysed using STATA®. 
Results: Of 380 cases reviewed, 90% had severe disease; the median age was 9.4 months (IQR 
4.8-23). Of these 89 (23%) were LBW (<2500g) and 75 (20%) were born premature. Median age 
at presentation for these groups was 5.7 months compared with 10.6 months in term children 
(p=0.0003). Forty-one (12%) were severely malnourished; 34 (9%) were HIV-positive. Children 
below 10/12 were more likely to have incomplete immunisations (57/190, p=0.011). Only 15% 
of TB-exposed children <5 years were on Isoniazid Prevention Therapy (IPT). Prevalence of 
comorbid conditions was high. Median duration of stay was 3 days (IQR 2-6); this increased to 
6.5 (IQR 4.5-9.5) with neurological disease and 6 (IQR4-10) with proven RSV. Seventeen patients 
(4.5%) required transfer to tertiary level. Mortality rate was 0.5%. 
Conclusion: Preventative measures must focus on populations at risk- LBW and preterm 
children in first year of life, malnourished children and those with comorbidities like HIV. 
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5). CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
5.1 Background: 
Despite a thirty percent reduction in pneumonia incidence since 2010[1], pneumonia still remains 
the leading cause of death in the under-five age group, excluding neonatal causes[2]. Pneumonia 
accounts for approximately 15% of deaths in this age group[3] and globally was responsible for 
0.935 million deaths in children under the age of five in 2013[2], 0.493 million of which were in 
Sub-Saharan Africa[2]. Children less than two years of age are at increased risk of mortality[1,4–8].   
African regions are reported to have an incidence rate of 0.27 episodes per child-year[1,9], and are 
over-represented in the numbers[1,7]. A recent birth cohort study in the Western Cape estimated 
the incidence of severe pneumonia to be 0.06 episodes per child year[9]. Pneumonia thus 
contributes significantly to both morbidity and hospital costs in Africa[10]. 
Acute complications from CAP include: parapneumonic effusions, necrotising pneumonia and 
lung abscesses[11], sepsis and metastatic infection[12] and rarely haemolytic uraemic syndrome[12]. 
Childhood pneumonia also has long term sequelae including chronic restrictive, obstructive and 
suppurative lung disease, which has been documented in up to 13.6% of children admitted to 
hospital[13]. There is a significant association between CAP under three years of age and asthma 
and impaired lung function in adulthood. Thus childhood lower respiratory tract infection (LRTI) 
can lead to chronic respiratory health issues in adulthood[14]. 
5.2 Objectives: 
The objectives of this literature review were to describe the incidence, epidemiology and 
aetiology of paediatric pneumonia, and how this has been effected by the introduction of the 
pneumococcal conjugate vaccine. To review the risk factors for pneumonia, especially those that 
are considered relevant to South Africa. And lastly to review recommendations for both special 
investigation and management of childhood community acquired pneumonia.  
5.3 Literature Search Strategy: 
The literature search was done using the pubmed search engine 
(http://www.ncbi.nlm.nih.gov/pubmed) and the following search strings: 
• Childhood pneumonia incidence Africa 
• Childhood severe pneumonia risk factors 
• Childhood pneumonia mortality outcome 
• Childhood community acquired pneumonia aetiology epidemiology 
• Childhood community acquired pneumonia management 
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The initial search was done in 2012 and a second search was done in 2015. Articles were 
included if the study subjects were derived from the paediatric population, regardless of study 
design. Neonates were excluded as they did not form part of the group studied at New Somerset 
Hospital and management protocols for neonates often differ from standard paediatric practice. 
Only English articles were included in the review. Preference was given to articles from the 
developing world. 
Reference lists of articles were reviewed to broaden the search strategy and additional articles 
were included on recommendation of either the supervisor or experts in the field. 
Search Results: 
The search strategy yielded 85 relevant studies; additional studies were included from reference 
lists of these articles and on recommendation; a total of 112 full text articles were reviewed. 
Fifty-four articles were eventually referenced. 
The majority of the articles were from the latter part of the last decade, but one article from 2005 
and two from 2002 were also included. 
5.4 Pneumonia aetiology: 
Childhood pneumonia can be caused by a variety of organisms, however microbiological data 
remains unreliable in the diagnosis of pneumonia[15].  
Streptococcus pneumoniae and Haemophilus influenza are vaccine preventable causes of 
pneumonia thought to be responsible for 33% and 17% of pneumonia deaths worldwide 
respectively[1]. Influenza contributes a further 11% to pneumonia deaths[1]. Bacterial pneumonia 
is most commonly caused by Streptococcus pneumoniae[10]. The second most common bacterial 
cause of pneumonia is Streptococcus pyogenes and Staphylococcus aureus, which are 
responsible for substantial morbidity[16]. Mycoplasma pneumoniae, which is more common in 
children over the age of three[1], and to a lesser degree Chlamydia trachomatis, play a significant 
role in hospitalised children[17].  
RSV is a virus, which when detected, is consistently implicated in disease[16]. Many studies have 
emphasised the role of mixed infection with either viruses or bacteria[10,12,15–19].  
HIV-positive children are more susceptible to pneumonia[20], and are effected by additional 
aetiologies; these include gram-negative bacteria, pneumocystis jiroveci (PJP) and 
cytomegalovirus (CMV). PJP is more prevalent in infants and is associated with a 50% fatality 
rate[20]. Rates of coinfection with PJP and CMV are high[21].  




5.5 Pneumonia and vaccine prevention: 
The conjugate haemophilus influenza vaccine was rolled out in South Africa in 1998. 
Worldwide, since introduction of the vaccine, pneumonia secondary to this organism has become 
rare[10,16]. Carriage of non-vaccine serotypes remains, but these seldom cause invasive disease[16]. 
The seven valent pneumococcal conjugate vaccine was introduced into the expanded programme 
of immunisation in 2009 and was replaced by a thirteen valent vaccine in May 2011[23]. Doses of 
PCV are given at six and fourteen weeks of age, with a booster dose at nine months. 
PCV-7 and PCV-13 have led to significant reductions in invasive pneumococcal disease in 
children under the age of five in the UK and USA (56% and 64% reduction in invasive disease 
from the pre-PCV7 era respectively), despite replacement disease [6,24].  
Use of pneumococcal vaccination was noted to have led to increased nasal carriage rate of non-
vaccine serotypes after introduction[6]. These serotypes, however, were not associated with a 
higher incidence of drug resistant strains[6,12,16,24] and some serotypes were thought to have lower 
invasive potential[6,22]. The incidence of non-vaccine serotype invasive disease in the UK has 
increased four years after introduction of PCV13, but the overall incidence of pneumococcal 
invasive disease is still on the decline[6]. With high vaccine coverage rates, there may be a 
change in aetiology of pneumonia, which in turn may affect future presentations of disease and 
will deserve further attention[1]. 
The reduction in invasive pneumococcal disease in older unvaccinated age groups is attributable 
to herd immunity from the serotypes included in PCV13[6,22,24,25]. 
Use of PCV in South Africa has been an effective intervention against bacterial pneumonia, a 
recent cohort study looking at HIV uninfected children, estimated a vaccine efficiency rate of 
39.2% in children (16-103 weeks of age) who had received all three doses of PCV[23]. 
Worldwide PCV7 has led to a decline in all cause pneumonia admissions[26].  
Children older than six months and less than five years, those who are HIV-positive and those 
who have a chronic disease; are currently recommended to receive the trivalent inactivated 
influenza vaccine (IIV)[27]. Pregnant women are also recommended IIV as they have a higher 
risk of mortality with influenza infection and to provide passive immunity to their children[27]. 
IIV is less effective in children less than two years and HIV-positive children; however it does 
provide some protection and is thus still recommended[28]. Vaccine efficacy is reliant on how 
accurately the vaccine is matched to circulating strains[28]. 
New methods in preventing RSV are under development, including maternal immunisation, 





5.6 HIV and the impact on pneumonia: 
In South Africa in 2015 there were an estimated 6.19 million people (11.2 percent of the 
population) living with HIV/AIDS[30]. Sub-Saharan Africa is at the epicentre of the HIV and the 
Tuberculosis epidemics[31]. HIV has had a significant impact on both morbidity and mortality 
from pneumonia[7]. 
HIV infected children have a higher incidence of lower respiratory tract infections in their 
lifetime[1,18,21]. These children have a higher rate of coinfection with viruses, bacteria and 
opportunistic organisms[18,21], and a greater case fatality rate compared with their HIV-uninfected 
counterparts[18,20,21]. This group of children require a unique approach to management, with 
preventative strategies such as highly active antiretroviral therapy, immunisation and bactrim 
prophylaxis playing an important role[18]. 
HIV exposed but uninfected (HEU) children represent a unique group with proven increased risk 
for hospital admission[32], opportunistic infection[32] and pneumonia outcomes which are 
intermediate between HIV infected and HIV unexposed children[20]. This risk could be 
attenuated by early maternal antiretroviral therapy[32]. 
Antiretrovirals were rolled out in the public sector in 2004, according to initiation criteria of a 
CD4 count of less than two hundred. By 2011,  seventy-nine percent of adults with a CD4 of < 
200 were receiving HAART[33]. Unfortunately roll out of paediatric antiretrovirals had not 
attained the same success[33].  
Currently in South Africa, all children under the age of five and any child with symptomatic 
WHO stage three or four HIV infection, or a CD4 count of less than five hundred, qualify for 
antiretroviral therapy (ART) initiation[34]. 
In 2013 UNAIDS reported that almost fifty percent of HIV positive children under fourteen 
years in South Africa, had access to antiretrovirals[35], which is a vast improvement on previous 
numbers. 
The roll out of  prevention of mother to child transmission (PMTCT) and the subsequent 
improvement in PMTCT guidelines has led to a dramatic reduction in perinatal conversion rates, 
with only an estimated 2.7% of HIV exposed infants testing positive at eight week follow-up in 
2012[36]. There is however, a further risk of seroconversion with ongoing HIV exposure. 
In December 2014 the National consolidated guidelines for prevention of mother to child 
transmission were published and a policy of immediate initiation of lifelong ART for all HIV-
positive pregnant or breastfeeding women, regardless of CD4 count, was adopted, (Option 
B+)[36]. 
With better access to HAART and an improved programme of PMTCT, HIV associated lung 




5.7 Tuberculosis and pneumonia: 
South Africa is considered an endemic area for tuberculosis and in 2014 had the sixth highest 
incidence rate of tuberculosis worldwide[31]. The incidence rate in children is suspected to be 
50% of that recorded in adults[37] and is probably underestimated in high burden areas[38]. Factors 
influencing this, common to developed and developing countries,  include paucibacillary disease 
in children[38] and difficulty obtaining expectorated sputum samples[38,39]. Developing countries 
have the additional issue of resource constraints[38]. Globally tuberculosis is responsible for a 
similar mortality rate as HIV[31]. 
A recent meta-analysis has emphasised the importance of Tuberculosis in acute severe 
pneumonia[7], either as a direct cause or as a risk factor leading to secondary bacterial lower 
respiratory infection[1,7]. The incidence rate of pulmonary tuberculosis in children under five with 
severe acute malnutrition or HIV infection[37] has been documented as high as 12%. 
It is postulated that with the roll out of the pneumococcal conjugate vaccine and Haemophilus 
influenza vaccine, tuberculosis might be more commonly isolated as a causative organism in 
acute pneumonia[37]. 
5.8 Risk factors for pneumonia: 
The risk factors for pneumonia include younger age[1,9,12,16], with those under two years a 
particularly high risk group[1]. This was recently confirmed in a study in the Western Cape, 
where children under six months had the highest incidence of pneumonia[9]. 
Male children have a higher incidence of recorded pneumonia[1,9], this may be secondary to 
biological factors[8] or represent gender discrimination in health seeking behaviours[8,40], with 
families seeking help for male children more readily than their female children. One meta-
analysis reported a higher incidence of severe pneumonia in males[8], and yet another reported 
male sex as a likely risk factor for severe acute LRTI[41]. However, a more recent study, showed 
a fifteen percent increased risk of  mortality in female children with pneumonia[42]. 
Malnutrition is an established risk factor for pneumonia[5,9]. Twenty one percent of children in 
Sub-Saharan Africa are underweight for age, while up to 4.9 % of South African children are 
wasted[43]. 
Children with malnutrition are at risk of pneumonia[9], which is likely to be severe[41]. The risk of 
mortality increases for children with pneumonia and severe malnutrition[42,44,45] (RR2.9-121.2), 
compared to well-nourished children[44]. In moderate malnutrition the relative risks of mortality 
are also increased, (RR1.2-36.5)[44]. This is probably explained by effects on both cellular and 
humoral immunity[45]. Children with malnutrition are effected by different organisms than well-
nourished children and WHO clinical signs of pneumonia may not be as reliable[44].  
Stunting reflects chronic malnutrition[43] and is associated with an increase in pneumonia 
incidence and hospitalisation, as well as higher rate of treatment failure[46]. An estimated 40% of 
Sub-Saharan children under the age of five are stunted[43] and although the rate of stunting is 
declining, the rate of decline is slower in Sub-Saharan Africa[43]. 
In HIV infected children risk factors for community acquired pneumonia include a CD4 count of 
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less than fifteen percent and  a viral load of more than 100 000[47]. The diagnosis of 
Pneumocystis jiroveci pneumonia in HIV infected children carries a high mortality rate[12,42]. 
Other patient factors associated with severe lower respiratory tract infections or increased 
mortality risk include: low birth weight[41,42], insufficient breast feeding[41,42], comorbidity with 
measles[42] and chronic diseases[42]. Prematurity was a likely risk factor (as opposed to a definite 
risk factor) for severe pneumonia in one meta-analysis[41], however it has been associated with a 
higher mortality rate in another recent meta-analysis[42]. 
Tobacco smoke exposure[9], weight under 2500g at birth[5,41], lack of immunisation[5,41] and 
insufficient breastfeeding[5,41] are also associated with increased incidence and severity[41]. 
Maternal factors for child mortality, are low level of education and younger age[42].  
Environmental risk factors for pneumonia (that are also associated with increased risk of 
mortality[42]) include: exposure to tobacco smoke[9] and indoor air pollution[5,41,48] and often 
concomitant with this crowding[5,41] and poverty[48]. Lack of access to care is also linked to 
severity[49]. 
Within South Africa many of these risk factors are applicable. 
It is clear that socioeconomic and other potentially modifiable factors play an important role in 
incidence of severe pneumonia and in mortality from pneumonia, and that health policy needs to 
address all of these elements in order to make progress in improving the under-five mortality 
rate. Focus will need to be on children under the age of two years to have greatest effect[1]. 
5.9 Investigation and management of pneumonia: 
There are comprehensive local and international guidelines available for the management of 
childhood community acquired pneumonia, including those by the South African Thoracic 
Society (SATS) and the British Thoracic Society (BTS). The BTS published guidelines for the 
management of community acquired pneumonia in 2011 and has developed a validated 
paediatric audit tool to be used for evaluating case management of pneumonia[12]. 
BTS guidelines do not incorporate management of HIV-infected children or children with pre-
existing respiratory conditions nor do they address the management of bronchiolitis or other mild 
respiratory illnesses. SATS guidelines address pneumonia in both HIV infected and uninfected 
children[10]. 
Stepwise approach to management includes clinical evaluation for presence of pneumonia and 
thereafter an assessment of severity, need for hospitalisation and oxygen therapy[12].  
In both guidelines routine use of chest x-ray (CXR) and inflammatory markers is discouraged[12]. 
A CXR is indicated only if there is suspicion of complication, foreign body, tuberculosis or 
failure to respond to standard treatment[10].  
Although the CXR has commonly been used in the diagnosis of childhood pneumonia and for 
assessing severity[50], it cannot distinguish viral from bacterial CAP[51]. Currently there is no 
single reliable gold standard to distinguish between viral and bacterial disease[39,51]. Leukocytosis 
is not helpful in distinguishing aetiology in both children and adults[39]. A serum CRP of more 
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than 40mg/l has a positive predictive value of 64% for bacterial pneumonia in children[52]. PCT 
is no more helpful in distinguishing severe disease than CRP[50]. There is disagreement between 
studies which looked at the effectiveness of PCT in differentiating viral and bacterial causes in 
children[39], PCT may be more useful in adult patients[39].  
Indicators of severe disease include signs of significant respiratory distress, apnoea, poor 
feeding, shock, hypoxia or cyanosis and underlying chronic disease[12].Severe disease should be 
identified and these children require admission, while children with mild to moderate 
pneumonias can usually be managed at outpatient community level[12]. Any concern on the part 
of the medical doctor that the family will not be able to administer or access care is a further 
motivating factor for hospitalisation[10]. 
Microbiological diagnosis is only recommended for children who have severe disease[10] and are 
admitted[10], or those that have complications of pneumonia or fail to respond to treatment within 
48 hours[12].  
Recent studies have shown that the yield of positive blood culture is low in community acquired 
pneumonia with prevalence of just over five percent[53] therefore a negative blood culture does 
not assist in making decisions related to antibiotic prescription[53] Limitations of the blood 
culture include time to result[39], high rate of false positive and negative cultures[39] and the 
invasive nature of the test itself[51]. Urine antigen tests for Streptococcus pneumoniae are not 
recommended in making a decision about antibiotics in children, because of the high rate of false 
positives secondary to colonisation[39]. PCR shows promise for organism detection, but is limited 
by availability[39] and cost. 
As it is difficult to differentiate viral and bacterial pneumonia, antibiotics are  recommended if a 
clinical diagnosis of pneumonia has been made[12]. Viruses are more common in children under 
two[12]. The BTS guidelines suggest a watch and wait approach in fully vaccinated children 
under two years of age with mild symptoms, but antibiotics must be initiated if any concerns 
arise with review[12]. High dose amoxicillin is first line therapy in children who tolerate oral 
therapy- higher doses overcome resistance of streptococcus pneumoniae to penicillin[10,12]. Oral 
amoxicillin is equally as efficien as intravenous therapy[10,12]. Macrolide antibiotics are added if 
there is suspicion for atypical organisms[12]. If staphylococcal infection is suspected cloxacillin 
should be used. 
Children under two months, malnourished and HIV positive children, or those with a clinical 
suspicion of HIV, should be covered for gram negative organisms with an aminoglycoside in 
addition to a beta-lactam[10]. HIV positive children should routinely receive cotrimoxozole cover 
for Pneumocystis jiroveci and steroids if hypoxia is present[10]. 
Supportive management includes oxygen, antipyretics, analgesia, fluid and nutrition[10]. Hypoxia 
at presentation increases risk of mortality[54] and improving access to saturation monitoring and 
oxygen therapy has been shown to decrease mortality[54]. 
Studies have suggested that community case management of pneumonia, with prescription of 
antibiotics, may reduce acute lower respiratory tract infection mortality by up to 70%[54]. In the 
Western Cape the Integrated Management of Childhood Illness (IMCI) is one such effective 
program[54] which was introduced in 2009 to improve access to care[10]. Ineffective health 
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systems are directly linked to an increase in pneumonia associated deaths[22]. It is therefore 
important in a resource limited setting such as South Africa to streamline the management of all 
illnesses including pneumonia. 
5.10 Summary: 
Children in South Africa have a high incidence of pneumonia in early life[9]. Pneumonia 
contributes significantly to the under-five mortality rate[2] and may have lasting consequences for 
adult respiratory health[14].  
Routine immunisation with PCV is likely to change pneumonia aetiology and viruses and 
Tuberculosis may be more commonly isolated in acute pneumonia[37].  
The epidemiology in our province has not been described at regional level since 2004, when 
HAART was rolled out in the public sector and since routine immunisation with PCV13.  
Many of the identified risk factors for CAP are prevalent in our setting with health economic 
factors playing an important role. 
It is hoped that through further research and a greater understanding of clinical presentation, 
recommendations for prevention and management of CAP could be made, which in turn could 
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Background: Pneumonia is a leading cause of death in children under-five. Epidemiology in our 
province at regional level has not been described since 2004, when HAART was rolled out and 
pneumococcal conjugate vaccination (PCV) was introduced. 
Objectives: Describe the demographic profile, disease severity, risks for transfer and mortality 
and the management of children >2 months, admitted with CAP over a one year period. 
Methods: Retrospective descriptive study of every second patient (>2 months to 13 years) 
admitted to Somerset Hospital in 2012 with the diagnosis of CAP. Demographic, clinical and 
outcome data were extracted from hospital records and analysed using STATA®. 
Results: Of 380 cases reviewed, 90% had severe disease; the median age was 9.4 months (IQR 
4.8-23). Of these 89 (23%) were LBW (<2500g) and 75 (20%) were born premature. Median age 
at presentation for these groups was 5.7 months compared with 10.6 months in term children 
(p=0.0003). Forty-one (12%) were severely malnourished; 34 (9%) were HIV-positive. Children 
below 10/12 were more likely to have incomplete immunisations (57/190, p=0.011). Only 15% 
of TB-exposed children <5 years were on Isoniazid Prevention Therapy (IPT). Prevalence of 
comorbid conditions was high. Median duration of stay was 3 days (IQR 2-6); this increased to 
6.5 (IQR 4.5-9.5) with neurological disease and 6 (IQR4-10) with proven RSV. Seventeen patients 
(4.5%) required transfer to tertiary level. Mortality rate was 0.5%. 
Conclusion: Preventative measures must focus on populations at risk- LBW and preterm 
children in first year of life, malnourished children and those with comorbidities like HIV. 












6.3 Introduction  
Pneumonia incidence has decreased by more than 30% since 2010[1], yet remains the leading 
cause of death in the under-five age group, excluding neonatal causes[2]. Children under two  
years are at increased risk of mortality[1,3,4]. African regions are reported to have an incidence 
rate of 0.27 episodes of pneumonia per child-year[1,5], and are over-represented in the numbers[1]. 
Community acquired pneumonia (CAP) thus contributes significantly to both morbidity and 
hospital costs in Africa[6]. 
Children hospitalised with pneumonia have a 13.6% risk of developing subsequent chronic 
restrictive, obstructive or suppurative lung disease[7]. There is an association with CAP prior to 
three years of age, and asthma and impaired lung function which persists into adulthood. Thus 
origins of some chronic adult respiratory health issues may be in childhood[8]. 
Streptococcus pneumoniae and Haemophilus influenza are vaccine preventable causes of 
pneumonia, responsible for 33% and 17% of pneumonia deaths worldwide respectively[1]. The 
conjugate haemophilus influenza (HiB) and seven-valent pneumococcal conjugate vaccine 
(PCV7) were rolled out in South Africa (SA) in 1998 and 2009 respectively, PCV 13 replaced 
PCV7 in May 2011[9]. Haemophilus influenza disease has since become rare[10]. Vaccination with 
PCV has led to significant reductions in invasive pneumococcal disease (IPD) in children under 
five[11–13] and in older unvaccinated age groups[11–13]. The latter is attributable to herd 
immunity[11,13,14].  
Worldwide PCV has led to a decline in all-cause pneumonia admissions[13,14], and has shown 
significant efficacy in preventing bacterial pneumonia in HIV-negative children in SA[9]. The 
increased incidence of non-vaccine serotype IPD[11,12] in some age groups, has been offset by the 
decline in vaccine-sensitive strains, so that overall incidence is still declining[11,12]. 
High vaccine coverage rates in SA may be associated with a change in aetiology of pneumonia, 
which in turn could affect future presentation of disease. Viral causes may become more 
prominent[15] and Mycobacterium Tuberculosis may be more commonly isolated in acute 
pneumonia[16]. 
Sub-Saharan Africa is at the epicentre of the HIV and Tuberculosis epidemics[17]. HIV-positive 
children have a greater incidence of pneumonia[15,18,19] and a higher case fatality rate [15,18]. HIV-
exposed uninfected (HEU) children are a unique group, who are at increased risk for severe 
pneumonia[20] and have pneumonia outcomes which are intermediate between HIV-infected and 
HIV-unexposed children[19,20]. 
In SA, 9% of children under-five are underweight-for-age, 5% are wasted and 24% are 
stunted[21]. Malnutrition is an established risk factor for pneumonia[5,22]. 
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Other patient factors associated with increased risk of severe lower respiratory tract infections 
(LRTI) or increased mortality risk include: low birth weight (LBW)[23,24], insufficient breast 
feeding[23,24], comorbidity with measles[23] and chronic diseases[23]. Prematurity is a likely risk 
factor for severe pneumonia[24] and has been associated with a higher mortality rate[23]. 
Environmental risk factors for severe pneumonia and higher mortality rate include, passive 
smoking and indoor air pollution[23,24].  
Improved access to antibiotics and community case management are protective against 
childhood mortality[25], while limited access is associated with severe disease[26]. Lower 
socioeconomic status is linked to higher mortality[23]. 
Within SA many of these risk factors are applicable and it is clear that socioeconomic and other 
potentially modifiable factors play an important role in incidence of severe pneumonia and in 
mortality from pneumonia.  
There are comprehensive local and international guidelines available for the management of 
childhood CAP, including those written by the South African Thoracic Society (SATS)[6] and the 
British Thoracic Society (BTS)[27]. 
The epidemiology in our province has not been described at regional level since 2004, when 
HAART was rolled out in the public sector and since routine immunisation with PCV13.  
Using the BTS tool we evaluated epidemiology, prevalence of risk factors for severity and 
transfer, hospital management and outcomes of CAP at our secondary level hospital. 
 
6.4 Methods: 
Study site:  
New Somerset Hospital is a 330-bed general regional hospital that serves the Western sub-
district of the Cape Metropolitan district and the West Coast. The paediatric population served is 
approximately 100 000[28], mostly middle and lower socio-economic backgrounds. 
Study Design and Patient Selection: 
We performed a retrospective descriptive study of every second patient (>2 months to 13 years) 
admitted to New Somerset Hospital (NSH) between 1 January and 31 December 2012 with the 
diagnosis of CAP or LRTI- regardless of causative organism or severity. Transfers in for 
ongoing management, from both tertiary and district hospital, were included. Patients were 
identified through the ward admission books and clinicom database. Children with acute 
exacerbation of asthma, without signs and symptoms of pneumonia, were excluded.  
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CAP was defined according to SATS Guidelines as ‘an acute infection of <14 days duration, 
acquired in the community, of the lower respiratory tract, leading to cough or difficulty 
breathing, tachypnoea or chest wall in drawing’[6]. BTS guidelines were used to define severe 
infection (Appendix 4)[6]. These definitions would include children with probable viral 
bronchiolitis. 
 
Data Collection and Analysis: 
The folders of identified patients were drawn from medical records, reviewed by the principal 
researcher and entered on an electronic data capture sheet (Microsoft Access®). Outstanding 
results were followed up through the National Health Laboratory Service (NHLS). 
Data collected comprised patient demographic information: HIV status, social circumstances, 
nutritional status and presence of comorbidity. Indicators of disease severity, results of 
investigations and information on management: antibiotic and oxygen use. Outcome data 
included: duration of stay, necessity for transfer to tertiary level and mortality. Decision to 
transfer was based on clinical decision that additional respiratory support was required (high 
flow oxygen, continuous positive airway pressure or ventilation). 
Data was analysed using STATA®/IC 11.1 for Windows Data Analysis and Statistical Software 
(StataCorp LP, TX77845, USA).  Data was tested for normality using the Shapiro-Wilks. Data 
was presented as medians (interquartile ranges) or means (SD) for non-normally and normally 
distributed data respectively. Chi-squared or Fishers exact test were used for comparison of 
categorical data with wilcoxon rank sum or t tests used to compare continuous data. Logistic 
regression analysis was conducted to determine which clinically relevant factors were associated 
with severity or transfer to tertiary level. For all tests a p-value <0.05 was considered significant. 
Permission to conduct this study was obtained from the Human Research Ethics Committee 
(HREC REF: 543/2013) and the need for informed consent was waived owing to the 
retrospective nature of the study. 
6.5 Results: 
In the period 01 January to 31 December 2012, 970 cases were initially identified. Of these 209 
cases were excluded: 54 folders did not meet criteria for CAP or were double entries, 13 folders 
could not be located and 142 were excluded based on age <2 months. We reviewed 380 






Demographics and Prevalence of Risk Factors:  
Table 1 shows the population characteristics. In this study 87% (332/380) of children were 
under-five years of age, median age of 9.4 months (IQR 4.8-23), with a slight male 
preponderance (p=0.48). 
There was a high percentage of ex-premature (22%) and LBW (25%) children. The median age 
of admission was 5.7 months for both these groups; significantly lower than the median age of 
the group of children born at term, (10.6 months, p=0.0003). 
HIV-positive children constituted 9% of the study group; of which 4% were newly diagnosed 
and 2% defaulted treatment. Of the children admitted 17% were documented as HEU and 14% 
were HIV untested.  
Of the studied group; 1% were obese (BMI>30), 9% were moderately- and 12% were severely-
malnourished (WHO child growth standards). Excluding HIV, prematurity and LBW; 22% of 
children had another chronic illness. Respiratory comorbidity was the most common (Table1). 
Immunisation was incomplete in 25%, this number increased to 30% in children ≤ ten months of 
age. 
Of those under-five years 16% were recently exposed to household tuberculosis, only 15% of 
this group were on IPT.  Previous Pulmonary Tuberculosis (PTB) was recorded in 6% of the 
overall group; however 27% of the HIV-positive group had previous PTB. 
One 4 month old HIV-positive child who had defaulted ART had proven PJP; while 5 children (4 
newly diagnosed and one who had defaulted ART) had a Cytomegalovirus (CMV) viral load > 
5000 and were treated for CMV disease. 
Management: 
Table 2 shows investigations performed. The most common was a chest radiograph (91%); 80% 
had a white cell count (WCC) and 51% had a C-reactive protein (CRP).  
Of those children who had severe disease 27% (55/202) had a WCC>18 x109/l, while of those 
with mild/moderate disease 5% (1/21) had a WCC >18x109/l, (p=0.024). A CRP of ≥ 40mg/l did 
not correlate with disease severity.  
Blood culture was taken in 57%; 24 cases cultured an organism, 88% of these were skin 
commensals. There was one proven case of penicillin-sensitive IPD in an unimmunised child. 
Two cases cultured gram-negative organisms, sensitive to either ampicillin or gentamicin. 
Antibiotics were issued in 96% of cases; 54% received ampicillin or amoxicillin, whilst 37% 
received ampicillin and gentamicin.  
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Of the HIV positive children 71.4% (20/28) received ampicillin and gentamicin, while 71.4% 
(137/242) of the HIV negative children received ampicillin/amoxicillin (p<0.0001). Of the 
children who were severely malnourished 69.7% (23/33) received ampicillin and gentamicin, 
while 63.3% (143/246) of the well-nourished children received ampicillin/amoxicillin (p=0.001). 
Excluding the children who were HIV positive and severely malnourished, 34.6% (93/269) 
received treatment with an aminoglycoside. 
Tuberculosis treatment was initiated in 14%; but in only 7% was decision to treat based on 
positive microscopy, culture or PCR results. 
In 54% of cases supplemental oxygen was used. 
Severity of disease, duration of stay and mortality: 
Of the children admitted 90% had severe disease (BTS definition), while 10% had mild or 
moderate disease. Hypoxia was recorded in 37% of cases. Table 3 shows possible risk factors for 
severe disease in the studied children. 
Informal housing, malnutrition and HIV status were not significantly associated with severe 
disease. Of the LBW children, 83% were classified as having severe disease, whilst 91% of 
children with birth weight > 2500g had severe disease, this difference was significant (p=0.042).  
The median duration of stay was 3 days (IQR 2-6). Younger age at admission and isolation of 
adenovirus were not associated with longer duration. Isolation of Respiratory syncytial Virus 
(RSV), with or without other viruses (20%), increased the median stay to six days (IQR4-10, 
p<0.0001). Children with neurological comorbidity had a mean stay of 6.5 days (IQR 4.5-9.5, 
p=0.008).  
Transfer rate for disease requiring assisted ventilation (CPAP or IPPV) was 4.5%. The mortality 
rate of CAP at NSH was (2/380) 0.5%. 
Univariate analysis did not reveal an association between need to transfer and mortality; with 
either age, gender, LBW, prematurity or HIV status. However children with malnutrition were 
3.1 times more likely to be transferred or demise (p=0.069). 
 
6.6 Discussion: 
The median age at admission of nine months is in keeping with findings of previous studies, 
including a recent study from the Western Cape, which prove a high incidence of pneumonia in 
the first year of life[1,4,5]. The majority of pneumonia deaths occur in children under two years, 
suggesting that interventions should focus on these children[1].  
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In this study the high incidence of LBW and prematurity and younger age at admission of both 
of these groups, suggests that they are at risk for developing pneumonia. The LBW incidence in 
our study is higher than the background LBW rate of  16.4% and 16.8% for the Metro West 
district for January-June 2013 and 2014 respectively (Prof Anthony Westwood; Head of Metro 
West; personal communication).  
LBW children may have an impaired immune response which predisposes to infectious 
disease[29]. Healthy preterm children in the first few months have reduced lung function 
compared to well term children[30] and are at proven risk for RSV infection and hospitalisation 
for both RSV and community acquired alveolar pneumonia[31].  
The protective effect from severity in LBW children could be a result of excluding children ≤ 
two months, who have high potential for severe disease[23] or perhaps these results reflect bias on 
the part of the admitting physician; who may be more likely to admit a child with a significant 
neonatal history. 
In a study in 2001 of hospitalised children with pneumonia in Cape Town,  up to 20% were 
related to HIV disease [32], whereas only 9% of the children in our study were HIV-positive. The 
decreased prevalence of HIV-positive children in South Africa is a direct reflection of improved 
PMTCT guidelines and access[33]. In 1998 9.9% of HIV-positive children admitted with 
pneumonia were diagnosed with PJP[32], while we had only one proven case of PJP. This is to be 
expected with improved access to antiretrovirals for children[34] and standard provision of 
cotrimoxazole prevention therapy (CPT). 
A high proportion of children were HEU, however we could not prove increased incidence of 
severity for this group, this risk could be attenuated by early maternal ART[20]. 
The high prevalence of malnutrition and association with transfer and mortality (although not 
significant) is unsurprising. These children are known to be at increased risk of pneumonia[5] 
which is more likely to be severe[24]. The risk of mortality from CAP is increased with both 
severe[23,35,36] and moderate malnutrition[35], secondary to changes in cellular and humoral 
immunity[36]. Stunting reflects chronic malnutrition[21] and is associated with an increase in 
pneumonia incidence and hospitalisation and with higher rate of treatment failure[37].  
Children with chronic underlying conditions are at increased risk of mortality from CAP[23], 
although we could not prove an increased risk for transfer in these children, both of the children 
who demised with CAP at our hospital had significant genetic comorbidities. The high 
prevalence of comorbidity with CAP admissions and the increased duration of stay with 
neurological comorbidity, suggests that focused preventative strategies and case management is 
necessary in these children. 
South Africa is considered an endemic area for tuberculosis[17], which is reflected in the high 
number of Tuberculosis-exposed children. Tuberculosis in children is likely underestimated in 
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high burden areas[38]. We diagnosed 14% with PTB, most of which were classified as probable or 
possible cases. Recent studies have emphasised the importance of Tuberculosis in acute severe 
pneumonia[39], either as a direct cause or as a risk factor leading to secondary bacterial LRTI[1,39]. 
It is postulated that with successful implementation of PCV and Hib, Tuberculosis might be 
more commonly isolated as a causative organism in acute pneumonia[16]. IPT is an effective 
method of preventing progression to TB disease in exposed children under five[38]. 
Lack of immunisation is a known risk for severe CAP[24], the only child with proven IPD was 
unimmunised.  
Currently there is no single reliable gold standard to distinguish between viral and bacterial 
causes of CAP[40,41]. Leukocytosis is proven unhelpful in distinguishing aetiology[41]; 20% of 
cases in this study did not have a WCC; it is reasonable to assume that severe cases were more 
likely to have blood investigation. Therefore, despite a significant result, correlating leukocytosis 
with severity would be inaccurate. A serum CRP of > 40-60 mg/l is considered weakly predictive 
for bacterial pneumonia in children[42], we did not demonstrate this.  
Blood culture is currently recommended for children with severe disease[6]. However limitations 
include low yield (<10% positive in cases of CAP)[43], long duration to result and high 
percentage of false positives and negatives[41]. This is reflected in our findings. Improvements in 
culture technique and possibly selection of patients, who are most likely to benefit from culture, 
may be necessary. 
A high proportion of children had special investigations including chest radiograph and acute 
phase reactants, these are not routinely recommended in the investigation of CAP by BTS and 
SATS[6,27]. Adherence to peer-reviewed guidelines would reduce cost (and radiation exposure) 
among admitted children. 
Our hospital protocols recommend addition of gentamicin to amoxicillin/ampicillin in children 
over 2 months who are severely malnourished or HIV-infected. In accordance with this protocol, 
both  HIV positive and  malnourished children were significantly more likely to receive both 
ampicillin and gentamicin. However, a large proportion of children who were well-nourished and 
HIV negative received an aminoglycoside, which  suggests inappropriate aminoglycoside 
prescription 
Despite the fact that only 30% of children had a NPA sent for respiratory viruses, detection of 
RSV led to longer duration in hospital and therefore significant cost burden. RSV is the leading 
cause of viral pneumonia in children under two[44] and is linked to the development of paediatric 
asthma[45] and wheezing in infancy[44]. New preventative strategies against RSV include maternal 
immunisation, infant intranasal live-vaccines and passive immunisation with antibodies[45]. 
These measures could serve to reduce morbidity and the high cost burden associated with this 
illness. The public sector currently does not have access to any RSV preventative strategy. 
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The high proportion of severe pneumonia could be explained as children are pre-selected to be 
hospitalised at a regional hospital.  
Despite high levels of LBW, comorbid chronic illness, malnutrition and poor immunisation rates; 
mortality at NSH was low. On further review, the two children who demised had significant 
comorbidity and established limitation of intervention, which precluded them from further 
escalation of support. 
As this was a retrospective descriptive study it was limited by the data recorded in the admission 
notes- there was thus insufficient data to reliably analyse the effect of breast versus formula 
feeding and exposures like indoor air pollution and passive smoking- which are known to effect 
CAP presentation[23,24].  
We chose to look at children > two months of age, as management and causative organisms 
differ in the younger age groups. However exclusion of the younger group may have missed 
significant severe disease. 
Collecting every second admission meant that we could not analyse seasonality or identify 
children with repeat admissions accurately. The small number of transfers made analysis of risk 
factors in that group difficult, further studies looking at risk factors at tertiary level may be 
helpful. 
6.7 Conclusion and recommendations: 
To improve the under-five mortality rate preventative measures need to focus on at risk 
populations; LBW and preterm children in first year of life, those with co-morbidities like HIV 
and malnourished children.  
HIV remains a risk factor and strong PMTCT policies and provision of ART must remain a 
priority. 
The low rate of immunisation reflects a need to strengthen primary health care approaches. The 
poor provision of IPT is particularly alarming in view of the current TB epidemic. Community 
health workers may be helpful in identifying at risk children and providing accessible care, prior 
to hospital admission becoming necessary. 
We are concerned about the lack of adherence to peer reviewed guidelines in terms of 
unnecessary special investigations and aminoglycoside use, and this can be improved. The high 
false positive blood culture rate also requires attention. 
Proven RSV and concomitant neurological disease lead to longer duration of admission, new 




1 Walker CLF, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. 
Lancet 2013;381:1405-16. [http://dx.doi.org/10.1016/S0140-6736(13)60222-6] [PMID: 
23582727] 
2 Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child 
mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet 
2015;385:430–40. [http://dx.doi.org/10.1016/S0140-6736(14)61698-6] [PMID: 
23582727] 
3 Zar HJ, Ferkol TW. The Global Burden of Respiratory Disease-Impact on Child Health. 
Pediatr Pulmonol 2014;49:430–4. [http://dx.doi.org/10.1002/ppul.23030] [PMID: 
24610581] 
4 Nair H, Simões EAF, Rudan I, et al. Global and regional burden of hospital admissions 
for severe acute lower respiratory infections in young children in 2010 : a systematic 
analysis. Lancet 2013;381:1380–90. [http://dx.doi.org/10.1016/S0140-6736(12)61901-1] 
[PMID: 3986472] 
5 Roux DM, Myer L, Nicol MP, et al. Incidence and severity of childhood pneumonia in 
the first year of life in a South African birth cohort: the Drakenstein Child Health Study. 
Lancet Glob Heal 2015;3:e95–103. [http://dx.doi.org/10.1016/S2214-109X(14)70360-2] 
[PMID: 25617203] 
6 Zar HJ, Jeena P, Argent A, et al. Diagnosis and management of community-acquired 




7 Edmond K, Scott S, Korczak V, et al. Long term sequelae from childhood pneumonia; 
systematic review and meta-analysis. PLoS One 2012;7:e31239. . 
[http://dx.doi.org/10.1371/journal.pone.0031239] [PMID: 22384005] 
8 Chan JYC, Stern DA, Guerra S, et al. Pneumonia in childhood and impaired lung 
function in adults: a longitudinal study. Pediatrics 2015;135:607–16. 
[http://dx.doi.org/10.1542/peds.2014-3060] [PMID 25733757] 
9 Madhi SA, Groome MJ, Zar HJ, et al. Effectiveness of pneumococcal conjugate vaccine 
against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African 
children: a case-control study. Thorax 2015;70:1–7. [http://dx.doi.org/10.1136/thoraxjnl-
2014-206593] [PMID: 26092924] 
32 
 
10  Williams DJ, Shah SS. Community-Acquired Pneumonia in the Conjugate Vaccine Era. J 
Pediatric Infect Dis Soc 2012;1:1–5. [http://dx.doi.org/10.1093/jpids/pis101] [PMID: 
26619424] 
11  Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after 
its introduction: an observational cohort study. Lancet Infect Dis 2015;15:535–43. 
[http://dx.doi.org/10.1016/S1473-3099(15)70044-7] [PMID: 26008826] 
12  Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal 
conjugate vaccine in children on invasive pneumococcal disease in children and adults in 
the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 
2015;15:301–9. [http://dx.doi.org/10.1016/S1473-3099(14)71081-3] [PMID: 25656600] 
13  Fitzwater SP, Chandran A, Santosham M, et al. The Worldwide Impact of the Seven-
valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J 2012;31:501–8. 
[http://dx.doi.org/10.1097/INF.0b013e31824de9f6] [PMID: 22327872] 
14  Angoulvant F, Levy C, Grimprel E, et al. Early Impact of 13-Valent Pneumococcal 
Conjugate Vaccine on Community-Acquired Pneumonia in Children. Clin Infect Dis 
2014;58:918–24. [http://dx.doi.org/10.1093/cid/ciu006] [PMID: 24532543] 
15  Cohen C, Walaza S, Moyes J, et al. Epidemiology of Viral-associated Acute Lower 
Respiratory Tract Infection Among Children < 5 Years of Age in a High HIV Prevalence 
Setting, South Africa, 2009-2012. Pediatr Infect Dis J 2015;34:66–72. 
[http://dx.doi.org/10.1097/INF.0000000000000478] [PMID: 25093972] 
16  Chisti MJ, Ahmed T, Pietroni MAC, et al. Pulmonary Tuberculosis in Severely-
malnourished or HIV-infected Children with Pneumonia: A Review. J Health Popul Nutr 
2013;31:308–13. [PMID: 24288943] 
17  World Health Organisation. Global Tuberculosis Report 2015. Geneva: World Health 
Organisation, 2015. http://www.who.int/tb/publications/global_report/en/ (accessed 3 
January 2016) [http://dx.doi.org/10.1007/s13398-014-0173-7.2] 
18  Enarson PM, Gie RP, Enarson DA, et al. Impact of HIV on standard case management 
for severe pneumonia in children. Expert Rev Respir Med 2010;4:211–20. 
[http://dx.doi.org/10.1586/ers.10.14] [PMID: 20406087] 
19  Gray DM, Zar HJ. Community-acquired pneumonia in HIV-infected children: a global 
perspective. Curr Opin Pulm Med 2010;16:208–16. 
[http://dx.doi.org/10.1097/MCP.0b013e3283387984] [PMID: 20375782] 
33 
 
20  Mothers BH, Izadnegahdar R, Fox MP, et al. Revisiting Pneumonia and Exposure Status 
in Infants Born to HIV-infected Mothers. Pediatr Infect Dis J 2014;33:2013–5. 
[http://dx.doi.org/10.1097/INF.0b013e31829f0ade] [PMID: 24352190] 
21  UNICEF. Improving child nutrition. The achievable imperative for global progress. New 
York: UNICEF, 2013. www.unicef.org/publications/index.html (accessed 4 January 
2016) [http://dx.doi.org/978-92-806-4686-3]  
22  Rudan I, Boschi-pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood 
pneumonia. Bull World Heal Organ 2008;86:408–17. 
[http://dx.doi.org/10.2471/BLT.07.048769] [PMID: 18545744] 
23  Sonego M, Pellegrin MC, Becker G, et al. Risk Factors for Mortality from Acute Lower 
Respiratory Infections (ALRI) in Children under Five Years of Age in Low and Middle-
Income Countries: A Systematic Review and Meta-Analysis of Observational Studies. 
PLoS One 2015;10:e0116380. [http://dx.doi.org/10.1371/journal.pone.0116380] [PMID: 
25635911] 
24  Jackson S, Mathews KH, Pulanić D, et al. Risk factors for severe acute lower respiratory 
infections in children – a systematic review and meta-analysis. Croat Med J 
2013;54:110–21. [http://dx.doi.org/10.3325/cmj.2013.54.110] [PMID: 23630139] 
25  Theodoratou E, Al-Jilaihawi S, Woodward F, et al. The effect of case management on 
childhood pneumonia mortality in developing countries. Int J Epidemiol 2010;39:i155–
71. [http://dx.doi.org/10.1093/ije/dyq032] [PMID: 20348118] 
26  Onyango D, Kikuvi G, Omolo J. Risk factors of severe pneumonia among children aged 
2-59 months in western Kenya: a case control study. Pan Afr Med J 2012;13:1–13. 
[PMID: 23330036] 
27  Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management 
of community acquired pneumonia in children: update 2011. Thorax 2011;66:ii1–23. 
[http://dx.doi.org/10.1136/thoraxjnl-2011-200598] [PMID: 21903691] 
28 Department of Paediatrics and Child Health, University of Cape Town 
http://www.paediatrics.uct.ac.za/scah/partnerhospitals/somerset (accessed 15 January 2016) 
29  Raqib R, Dewan AS, Sarker P, et al. Low birth weight is associated with altered immune 
functions in rural Bangladeshi children: a birth cohort study. Am J Clin Nutr 
2007;85:845–52. [PMID: 17344508] 
30  Friedrich L, Stein RT, Pitrez PMC, et al. Reduced lung function in healthy preterm 
infants in the first months of life. Am J Respir Crit Care Med 2006;173:442–7. 
[http://dx.doi.org/10.1164/rccm.200503-444OC] [PMID: 16322648] 
34 
 
31  Greenberg D, Dagan R, Shany E, et al. Increased Risk for Respiratory Syncytial Virus-
associated, Community-acquired Alveolar Pneumonia in Infants Born at 31–36 Weeks of 
Gestation. Pediatr Infect Dis J 2014;33:381–6. 
[http://dx.doi.org/10.1097/INF.0000000000000130] [PMID: 24145171] 
32 Zar HJ, Hanslo D, Tannenbaum E, et al. Aetiology and outcome of pneumonia in human 
immunodeficiency virus-infected children hospitalized in South Africa. Acta Pediatr 
2001;90:119–25. [PMID: 11236037] 
33  National Department of Health. Joint Review of HIV, TB and PMTCT Programmes in 
South Africa October 2013. Durban: National Department of Health, 2013. 
http://www.health-e.org.za/wp-content/uploads/2014/04/who-final-report-of-joint-hiv-tb-
pmtct-main-report.pdf (accessed 3 January 2016) 
34 UNAIDS. 2014 Progress Report on the Global Plan towards the elimination of new HIV 
infections among children by 2015 and keeping their mothers alive. UNAIDS, 2015. 
http://www.unaids.org/sites/default/files/documents/JC2681_2014-Global-Plan-
progress_en.pdf (accessed 3 January 2016) 
35  Chisti MJ, Tebruegge M, Vincente S La, et al. Pneumonia in severely malnourished 
children in developing countries – mortality risk, aetiology and validity of WHO clinical 
signs: a systematic review. Trop Med Int Heal 2009;14:1173–89. 
[http://dx.doi.org/10.1111/j.1365-3156.2009.02364.x] [PMID: 19772545] 
36  Rodriguez L, Cervantes E, San A. Malnutrition and Gastrointestinal and Respiratory 
Infections in Children: A Public Health Problem. Int J Environ Res Public Health 
2011;8:1174–205. [http://dx.doi.org/10.3390/ijerph8041174] [PMID: 21695035] 
37  Moschovis PP, Addo-Yobo EOD, Banajeh S, et al. Stunting is associated with poor 
outcomes in childhood pneumonia. Trop Med Int Heal 2015;20:1320–8. 
[http://dx.doi.org/10.1111/tmi.12557] [PMID: 26083963] 
38  Marais BJ. Tuberculosis in children. J Paediatr Child Health 2014;50:759–67. 
[http://dx.doi.org/10.1111/jpc.12503] [PMID: 24548085] 
39 Oliwa JN, Karumbi JM, Marais BJ, et al. Tuberculosis as a cause or comorbidity of 
childhood pneumonia in tuberculosis-endemic areas : a systematic review. Lancet Respir 
Med 2015;3:235–43. [http://dx.doi.org/10.1016/S2213-2600(15)00028-4] [PMID: 
25648115] 
40 Lynch T, Bialy L, Kellner JD, et al. A Systematic Review on the Diagnosis of  Pediatric 
Bacterial Pneumonia: When Gold Is Bronze. PLoS One 2010;5:e11989. 
[http://dx.doi.org/10.1371/journal.pone.0011989] [PMID: 20700510] 
35 
 
41  Florin T, Ambroggio L. Biomarkers for community-acquired pneumonia in the 
emergency department. Curr Infect Dis Rep 2014;16:1–10. 
[http://dx.doi.org/10.1007/s11908-014-0451-8] [PMID: 25348745] 
42  Flood R, Badik J, Aronoff SC. The Utility of Serum C-Reactive Protein in Differentiating 
Bacterial from Nonbacterial Pneumonia in Children: A Meta- Analysis of 1230 Children. 
Pediatr Infect Dis J 2008;27:95–9. [http://dx.doi.org/10.1097/INF.0b013e318157aced] 
[PMID: 18174874] 
43  Iroh Tam P-Y, Bernstein E, Ma X, et al. Blood Culture in Evaluation of Pediatric 
Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Hosp 
Pediatr 2014;5:324–36. [http://dx.doi.org/10.1542/hpeds.2014-0138] [PMID: 26034164] 
44  Manikam L, Lakhanpaul M. Epidemiology of community acquired pneumonia. Paediatr 
Child Health (Oxford) 2012;22:299–306. [http://dx.doi.org/10.1016/j.paed.2012.05.002]  
45 Polack FP. The changing landscape of respiratory syncytial virus. Vaccine 













TABLE 1: Features of study population 
Demographic data No/No known % 
36 
 
Hospital of origin:   
From RCWMH*  103/380 27 
RCWMH from Informal settlement 39/102 38 
NSH admission† 277/380 73 
NSH from Informal settlement 111/270 41 
Gender:   
Male  210/380 55 
Female 170/380 45 
Age:   
Age (months) median, IQR 10.6 (4.8-23)  
Age males median IQR 10.6 (4.8-23)  
Age females median IQR 9 (4.8-24)  
Age LBW median IQR 5.7 (3.8-12)  
Age >2500g BW median IQR 10.6 (5.3-24)  
Age Ex-prem median IQR 5.7 (3.8-14.8)  
Age term median IQR 10.6 (5.7-24)  
Age HIV positive median IQR 35.4 (9-67)  
LBW babies 89/355 23 
Ex-premature babies 75/341 20 
HIV status:   
Exposed negative 65/380 17 
Exposed unknown 1/380 0.3 
Negative 226/380 60 
Positive default ART 7/380 2 
Positive on ART 11/380 3 
Positive preART 16/380 4 
Unknown 54/380 14 
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Immunisation:   
Immunisation incomplete (total) 87/354 25 
Immunisation incomplete (<10/12) 57/190 30 
Malnutrition:   
Moderate malnutrition 32/342 9 
Severe Malnutrition 41/342 12 
Obese 3/342 1 
Breastfed (at least 2/12 exclusively): 181/380 48 
Chronic illness: 84/380 22 
Cardiac 14/84 17 
Genetic 12/84 14 
Neurological 5/84 6 
Renal 1/84 1 
Respiratory 52/84 62 
Previous admission (last 6 months) 111/362 31 
Tuberculosis:   
TB exposed<5 years 53/332 16 
TB exposed <5 years on INH 8/53 15 
Previous PTB 21/380 5.5 
 
*  RCWMH (Specialist centre) down-refers children to NSH (Regional level); this includes children who originate from NSH drainage area  
and/or require further secondary level care. 





TABLE 2: Special investigations 
Special investigations and management 
Special investigations: No/No known % 
38 
 
Chest radiograph  348/380 92 
WCC 303/380 80 
CRP 195/380 51 
Blood culture 218/380 57 
Nasopharyngeal aspirate 101/380 27 
Induced sputum 115/380 30 
 
TABLE 3: Risk factors for severe disease 
No of severe cases/no of mild or moderate cases= % p-value 
Informal Formal housing   
124/142 (87.3%) 190/208 (91.3%)  p=0.422 
Ex-premature babies Term babies   
60/72 (83.3%) 227/252 (90%)  p=0.112 
LBW babies BW>2500g   
68/82 (82.9%) 232/255 (91%)  P=0.042 
Severe malnutrition Moderate malnutrition Normal nutrition  
35/37 (94.6%) 24/27 (89%) 227/258 (88%) p=0.720 
HEU HIV positive preART HIV negative  
59/65 (89.7%) 14/14 (100%) 181/209 (86.6%) p=0.127 
 
TABLE 4: Special investigations and relation to severity 
Severe disease:  
(CRP>40/Total ) ‡  
Mild/moderate disease:  
(CRP>40/Total ) ‡  
 
   
 48/168 (29%) 3/19 (16%) p=0.236 
   
Severe disease:  
(WCC>18/Total ) § 
Mild/moderate disease:  
(WCC<18/Total )  §  
 
 55/202 (27%) 1/21 (5%) P=0.024 
   
 
‡ CRP reported as milligram per litre (mg/l) 




TABLE 5: Use of Ampicillin and Gentamicin versus Amoxil/Ampicillin ¶ 







TOTAL  40.3% (129/320) TOTAL (191/320) 59.7% 
HIV negative 105/242 43.4% 137/242 56.6% 
HIV positive 20/28 71.4% 8/28 28.6% 




83/226 36.6% 143/226 63.3% 
Moderate Malnutrition 14/28 50% 14/28 50% 
Severe Malnutrition 23/33 69.7% 10/33 30.3% 
 
HIV and ≥Normal 
nutrition 
93/269 34.6% 176/269 65.4% 
 
















Supplementary Table 1: Respiratory Virus Panel Results 
Respiratory Virus Panel Results- Nasopharyngeal aspirates 
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RSV only 22/101 (22%) 
RSV±other viruses 7/101 (6.9%) 
Adenovirus only 11/101 (10.9%) 
Adenovirus±other viruses 4/101 (4%) 
Pertussis only 0 
Pertussis±other viruses 1/101 (1%) 
Parainfluenzae 4/101 (4%) 
Parainfluenze±other viruses 3/101 (3%) 
Influenzae 3/101 (3%) 
Influenzae±other viruses 0 
Metapneumonvirus 5/101 (5%) 
Metapneumovirus±other viruses 1/101 (1%) 
Rhinovirus 11/101 (10.9%) 
Rhinovirus ±other viruses 7/101 (6.9%) 
 
Supplementary list 1: Diagnosis of children with neurological comorbidity 
1. Spinal Muscular Atrophy 
2. Dravet Syndrome with severe developmental delay 
3. Spastic Cerebral Palsy 
4. Dystonic Cerebral Palsy 
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Pneumonia is the leading cause of mortality worldwide contributing 1.575 million deaths to the under-
five mortality rate in 2008  (1) and an estimated 18% to the worldwide under 5 mortality rate annually 
(2). In South Africa in 2007 lower respiratory tract infections were responsible for 15.1% of child deaths 
(1-4 years of age), only ranked below diarrhoeal diseases and ill-defined natural causes. (4) 
A quarter of children from the developing world will have one episode of pneumonia a year (5), 
therefore pneumonia contributes significantly to morbidity and hospital costs in Africa. (6)  
Although it is often difficult to isolate specific pathogens in childhood pneumonia, vaccine trial studies 
have been used to estimate the incidence of bacterial causes (7). In developing countries bacterial 
causes contribute significantly to both hospitalisation and mortality from pneumonia. (8). Viral isolates 
were found in 30-40% of children admitted to hospital in Cape Town with pneumonia (8), while 
respiratory syncitial virus is the leading viral cause of pneumonia in developing countries (7). 
Tuberculosis (TB) contributes to disease in both HIV (Human immunodeficiency virus) infected and 
uninfected children (7). South Africa is classified as a high TB burden country; in 2011 tuberculosis had 
an incidence rate of 993 per 100000 population. (9). Eight percent of pneumonia cases are reported 
secondary to tuberculosis in high TB/HIV prevalence areas (8, 10). 
 Co-infection with viruses and bacteria is not uncommon occurring in as many as two thirds of childhood 
pneumonia cases. (8) 
In 2008 an estimated 23-320 000 children between 1-14 years were suffering from HIV/AIDS (11). This is 
a population at greater risk for infectious disease, including opportunistic infections such as 
pneumocystis jivorcii (PJP), as well as a group at higher risk for adverse outcomes.(6,12,13). PJP was the 
causative organism in 20% of newly diagnosed HIV positive children hospitalised for severe pneumonia 
(12) and Mycobacterium tuberculosis also contributed (8). HIV positive patients hospitalized with PJP 
have a reported mortality between 20 and 63 percent. (10). CMV pneumonitis was noted as a cofactor 
in 30-40% of postmortem studies in HIV positive children. 
Antiretrovirals were rolled out in the public sector in South Africa in 2004 and according to initiation 
criteria of CD4 <200, 80% coverage of adults was attained in 2011 (14). Lower rates of initiation were 
recorded in children; but in 2011, 152000 children were receiving highly active antiretrovirals (HAART) 
as compared to 4200 in 2004. (14) The ratio of new children enrolled on HAART to number of newly 
diagnosed HIV positive children was 1.13 (95% CI 0.74-1.48) from mid-2010 to mid-2011 (14). With 
better access to HAART and programmes for Prevention of Mother to Child Transmission (PMTCT) of HIV  
for mothers, HIV associated lung disease would be expected to decline. 
Although there is a global reduction in the prevalence of children who are stunted and wasted, in South 
Africa an estimated 10-19.9% of children are underweight for age (weight for age <-2SD) and 20- 29-9% 
of children are stunted (Ht for age <-2SD) (15). Malnutrition (wt for age <-2SD) contributes 35% to 
overall childhood under 5 mortality rate (15), this is again a group of children who are at high risk for 
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morbidity and mortality from many infections, including pneumonia (7,13). Hypoxia and malnutrition 
are the strongest predictors for mortality in both HIV infected and uninfected children (16). 
There were 25929 low birth weight babies (1 kg to 2,5 kg) born in the Western Cape for the period 2010 
to 2011 (17). The low birth weight rate in the Western Cape is 16.66 % (14.7% for South Africa) (17). Low 
birth weight is a definite risk factor for the incidence of pneumonia in developing countries (7). 
Community case management and prescription of antibiotics in childhood pneumonia has proven to be 
beneficial in reducing acute lower respiratory tract infection mortality by 35% (6). In the Western Cape 
the Integrated Management of Childhood Illness (IMCI) is one such effective programme (18). 
Ineffective health systems are directly linked with an increase in pneumonia associated deaths (5), it is 
therefore important in a resource limited setting such as South Africa to streamline the management of 
all illnesses including pneumonia. 
The South African Extended Programme of Immunisation (EPI) includes immunization against Bortadella 
pertussis, Haemophilus influenza, measles and the pneumococcal conjugate vaccine. Immunization has 
had a significant effect on mortality and pneumonia rates (19). The pneumococcal vaccine was 
introduced into the expanded immunization programme in April 2009 and the Haemophilus conjugate 
vaccine introduced in 1998. The pneumococcal vaccine has the potential to decrease the incidence of 
pneumonia by 13-20% (10) and the Haemophilus influenza vaccine reduces invasive disease by as much 
as 93%, although it is not as effective in HIV positive children not on HAART. Vaccination rates are 
directly related to strength of health systems in the area as well as socioeconomic circumstances (13). 
There are comprehensive local and international guidelines available for the management of community 
acquired pneumonia (CAP), including those by the South African Thoracic Society (SATS) and the British 
Thoracic Society (BTS). The BTS has published guidelines for the management of community acquired 
pneumonia in 2011 and has developed a validated paediatric audit tool to be used for evaluating case 
management of pneumonia. Steps include clinical evaluation for presence of pneumonia and thereafter 
assessing severity and need for hospitalisation and oxygen therapy. Radiological diagnosis is only 
required in children to screen for complications, in suspected pulmonary tuberculosis or foreign body 
aspiration or in children unresponsive to standard treatments. In hospitalized children there should be 
an attempt to establish the causative organism, but this should not interfere with initiation of empirical 
therapy. The first choice antibiotic is amoxicillin but children less than two months of age should also 
receive aminoglycosides and HIV exposed children under six months of age, unless confirmed negative, 
should receive clotrimoxazole. Suspected staphylococcal pneumonia should be treated with cloxacillin. 
Supportive management includes oxygen, antipyretics and analgesic, fluids and nutrition.  Preventative 
measures include immunization, micronutrient supplementation, optimisation of nutrition, promotion 
of breast feeding as well as tuberculosis prophylaxis (16,20) 
In view of this common presentation, we decided to utilize the BTS tool to evaluate in hospital 
management at our secondary level hospital. Due to our unique patient population and the SATS 
guidelines we modified this to include additional aetiologies and management relevant to our setting 
44 
 
(see appendices  1 and 2). The epidemiology in our province has not been described since 2004 when 
HAART was rolled out in the public sector.  
Our hypothesis is that at our a secondary hospital many of our admissions will have underlying risk 
factors, the exact aetiology will often not be identified, and we anticipate a high incidence of TB and 
possibly a reduction in PJP considering the improved PMTCT programme, chemoprophylaxis for PJP and 





1. To describe the demographic profile, clinical presentation, severity , and investigation 
results (including aetiology where available),  of children admitted with a diagnosis of CAP 
over a 1 year period 
2. To describe management including antibiotic use 
3. To describe outcome including any mortality  
4. To determine the presence of co- morbidities, such as malnutrition, HIV infection, LBW, 
prematurity, lack of breast feeding that may be as associated  with a higher  incidence of 
severe pneumonia 
Secondary: 
1. To compare management to standard guidelines  
2. To compare aetiology with other studies in a similar setting 
3. To identify any potential need to modify local guidelines specific to our setting and findings 
 
Study design: 
Retrospective descriptive study 
 
Study identification or selection: 
All paediatric patients (>2 months to 13 years of age) admitted to New Somerset Hospital between 
January and December 2011 with the diagnosis of pneumonia or lower respiratory tract infection- 
regardless of causative organism or severity. 
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Patients transferred in from tertiary level with the above diagnosis, would also be included and the 
photocopied notes from the admitting doctor used for data entry. 
Every second folder of patients who meet the above criteria will be reviewed. 
 
Measurement: 
Instruments: Data will be captured directly onto an Access® data capture sheet, based on the BTS 
Pneumonia audit tool, but modified to include criteria significant to the South African population.  
Definitions:  
1. Paediatric: any patient under the age of 13 years, and within this study context, more than two 
months of age. 
2. Community acquired pneumonia: Acute infection of <14 days duration, acquired in the 
community, of the lower respiratory tract, leading to cough or difficulty breathing, tachypnoea 
or chest wall in drawing (20). 
3. Pneumonia: The WHO defines pneumonia as acute episode of cough or difficulty breathing 
associated with an increased respiratory rate, the underlying cause being viral or bacterial. 
(WHO) 
4. HIV positive: HIV PCR + <18 months of age with a confirmatory VL; or two positive HIV elisas on 
a child >18 months old. 
5. HIV exposed and negative: Mother positive in pregnancy and child tests PCR negative 
6. HIV exposed: Mom tested HIV positive, child’s status is unknown 
7. HIV negative: HIV unexposed child with a negative HIV test (Elisa or PCR) 
8. Unknown: No information on child or mothers status available 
9. Breast fed: Child under six months of age, breast fed exclusively for at least two months. 
10. Low birth weight: Less than 2500g at birth 
11. Preterm: Less than 37 weeks completed gestation at delivery  
12. Tachypnoeic for age: > 50 breaths per minute in a child 2-12 months of age and >40 breaths per 
minute for child 1-5 years of age. (20) 
13. Definite TB: Culture positive Mycobacterium Tuberculosis or MTB PCR positive 
 
Patient identification: 
Using the ward admission books from the two general admission paediatric wards, the names and folder 
numbers of all the children between 2 months and 13 years of age admitted to New Somerset Hospital 
over the period from January to December 2012 with a diagnosis of CAP/lower respiratory tract 
infection will be identified. The hospital clinicom database will also be searched for any children with the 
final discharge diagnosis of pneumonia or lower respiratory tract infection, to ensure no cases are 
missed. Children with an acute exacerbation of asthma, without signs and symptoms of pneumonia will 
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be excluded. The diagnosis of bronchiolitis would not qualify as exclusion criteria, but if the diagnosis 
was ‘likely bronchiolitis’ then this will be captured on the data capture sheet. 
The expected number of children to be included in this study is 808 (as per New Somerset Hospital 
admission book from 2012). However some of these children may be under the age of two months of 
age and therefore would not be included and other folders will not be included should records be 
incomplete. 
Data collection: 
The folders of the identified patients will be requested and drawn from medical records at New 
Somerset Hospital and will be reviewed by the principal researcher.  
Any culture results or blood results that are outstanding will be followed up by the principal researcher 
through the NHLS computer system and telephonically should it be necessary.  
This data will be directly entered on an electronic data collection  (Microsoft Access®) database (see 
Appendix). Each entry will record patient details: demographics, HIV status, social circumstances, 
nutritional status; indicators of disease severity; results of investigations and look at how the patient 
was managed and treated; as well as determine outcomes based on re-admission and adverse events. 
Data will be analysed by a University of Cape Town (UCT) statistician using appropriate descriptive and 
comparative statistics. Analysis will be using STATA ® 
Ethics: 
In order to maintain confidentiality each admission will receive a study number and the data collated 
onto the data collection forms will only bear this study number. The principal researcher however, will 
retain a copy of folder numbers correlated with study numbers so that a folder could be located again 
through medical records should it be necessary. This will be an electronic list, kept in a password 
encrypted folder. No published data will be linked to any specific patient. 
HIV results will be obtained from the folders, for which consent (as per hospital guidelines) will have 
been obtained by the clinician involved in care and management and the parents duly counselled. 
It will not be possible to obtain individual consent from the parents of each child involved because of the 
retrospective design, but management is not influenced or altered by the study. Consent for the use of 
medical records will be obtained from the hospital CEO with application to waive individual consent (see 
Appendix 3). 
Risks to participants: There are no risks to the participants as this is a retrospective study. 
Benefits to participants: There are no direct benefits to the patients in this study. However management 
guidelines at the local institution may be improved depending on results 
Reporting and implementation: 
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All results of data analysis will be reported back to the paediatric department of New Somerset hospital 
with the potential to improve future management. 
Budget: 
The study will be undertaken by the principal researcher as part of her MMED project under the 
University of Cape Town. There will be no personal compensation for the principal researcher or the 
supervisor. Only routine existing equipment available at New Somerset Hospital will be required. 
Expenses related to printing and internet will be covered by funding through the postgraduate 
committee allocated to training registrars research projects (R5000/student). This will be managed from 
the supervisors entity for incidental costs. Statistical support will be from the University allocated 
statistician at no additional cost 
Strengths and limitations: 
The study is limited by its retrospective nature -the accuracy of recorded notes and the availability of 
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Date of birth: In format: date/month/year 
Gender: Drop down boxes for male and female 
Housing: Drop down boxes for Formal/Informal/Unknown 
Low birth weight: Drop down boxes for Yes/No/Unknown 
Exprem: Drop down boxes for Yes/No/Unknown 
Feeds: Breastfed/Formula/Unknown 
Nutrition: Drop down boxes for normal, moderate malnutrition, severe malnutrition and unknown. 
Immunisation: Drop down boxes for up to date, not up to date, unknown. 
TB exposed: Drop down boxes for exposed, unexposed and unknown. 
Isoniazid prophylaxis therapy (IPT): Drop down boxes for yes, no, unknown and not applicable. 
Previous PTB: Drop down boxes for yes, no and unknown. 
HIV status: Drop down boxes for positive on HAART, positive pre-HAART, positive defaulted ARV’s, 
exposed but HIV status unknown, negative and unknown. 
Chronic illness: Drop down boxes for yes, no and unknown and then a block to include specific chronic 
illness. 
Preadmission antibiotic: Drop down boxes for yes, no and unknown. 
Admitted in last six months: Drop down boxes for yes, no and unknown. 
Transfer from RXH: In format yes/no 
Box for date of arrival at Red Cross: In format day/month/year 
Box for date of arrival NSH: In format day/month/year 
Box for date of discharge: In format day/month/year 





Signs of CAP: 
Box for respiratory rate: (To be recorded as breaths per minute)  
Tachynoeic for age: Drop down boxes for yes or no 
O2 saturation: Drop down boxes for <92 or >92 
Nasal flaring: Drop down boxes for yes, no and unknown. 
Recessions: Drop down boxes for yes, no and unknown. 
Apnoea: Drop down boxes for yes, no and unknown. 
Grunting: Drop down boxes for yes, no and unknown.  
Not feeding in an infant: Drop down boxes for yes, unknown an not applicable. 
Wheezing: Drop down boxes for yes, no and unknown. 
Highest temperature recorded: Box for value in degrees celsius 
Likely bronchiolitis: Drop down boxes for yes/no 
 
Work up: 
CXR: Drop down boxes for: not done, normal, abnormal, lobar pneumonia, not recorded: 
WCC: Drop down boxes for yes and no. Box for value to be recorded. 
CRP:  Drop down boxes for yes and no. Box for value to be recorded. 
Blood culture done:  Drop down boxes for yes and no. 
Organism cultured from blood culture: Drop down boxes for yes and no. 
Organism cultured from blood culture number 1: Drop down boxes for nil, streptococcus pneumonia, 
Haemophilus influenza, staphylococcus areus MRSA, staphylococcus aureus non-MRSA, mycoplasma 
pneumonia, chlamydia pneumonia, moraxhella catarrahlis, mycobacterium tuberculosis, skin 
commensal. 
Organism cultured from blood culture number 2: Drop down boxes for nil, streptococcus pneumonia, 
Haemophilus influenza, staphylococcus areus MRSA, staphylococcus aureus non-MRSA, mycoplasma 




NPA: Drop down boxes for done or not done. 
NPA 1 organism recovered: Drop down boxes for nil, RSV, corona virus, rhinovirus, influenza, 
parainfluenza, CMV, PJP, bocavirus, human metapneumovirus. 
NPA 2 organism recovered: Drop down boxes for nil, RSV, corona virus, rhinovirus, influenza, 
parainfluenza, CMV, PJP, bocavirus, human metapneumovirus. 
Induced sputum: Drop down boxes for done or not done. 
Induced sputum ‘number one’ results: Drop down boxes for RSV, metapneumovirus, rhinovirus, 
parainfluenza, influenza, CMV, PJP, bocavirus, Group A streptococcus, Haemophilus influenza, Staph 
aureus (MRSA), Staph aureus (non-MRSA), mycoplasma and chlamydia, moraxhella catarrhalis, MTB, 
commensal. 
Induced sputum ‘number two’ results: Drop down boxes for RSV, metapneumovirus, rhinovirus, 
parainfluenza, influenza, CMV, PJP, bocavirus, Group A streptococcus, Haemophilus influenza, Staph 
aureus (MRSA), Staph aureus (non-MRSA), mycoplasma and chlamydia, moraxhella catarrhalis, MTB, 
commensal. 
Gastric washing: Drop down boxes for done or not done. 
Gastric washing ‘number one’ results: AFB positive and culture positive, AFB negative and culture 
positive, AFB and culture negative. 
Gastric washing ‘number one’ results: AFB positive and culture positive, AFB negative and culture 
positive, AFB and culture negative. 
CMV viral load: Drop down boxes for <5000, >5000, not done. 
Management: 
O2 given- (Given anytime): Drop down boxes for yes, no and not recorded. 
Bronchodilators given: Drop down boxes for yes, no and not recorded. 
Hypertonic saline nebs given: Drop down boxes for yes, no and not recorded. 
Antibiotics used: 
1 Antibiotic: First line antibiotics: Drop down boxes for amoxicillin, augmentin, erythromycin, 
flucloxacillin, cefalexin, cefuroxime, oseltamavir, bactrim oral, antituberculous medication, oseltamavir, 
ampicillin, gentamycin, amikacin, piptazobactem, cloxacillin, ceftriaxone, cefotaxime, cefuroxime, 
vancomycin, ertapenem, meropenem, iv bactrim, gangcyclovir. (Four options of drugs as first line: 
1Antibiotic1, 1Antibiotic2,1Antibiotic3, 1Antibiotic4) 
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2 Antibiotic: Second line antibiotics: Drop down boxes for amoxicillin, augmentin, erythromycin, 
flucloxacillin, cefalexin, cefuroxime, oseltamavir, bactrim oral, antituberculous medication, oseltamavir, 
ampicillin, gentamycin, amikacin, piptazobactem, cloxacillin, ceftriaxone, cefotaxime, cefuroxime, 
vancomycin, ertapenem, meropenem, iv bactrim, gangcyclovir. (Four options of drugs as second line: 
2Antibiotic1, 2Antibiotic2,2Antibiotic3, 2Antibiotic4) 
Duration of therapy? 
Complications of Therapy: 
Drop down boxes for yes, no or not recorded. 
Drop down boxes for complications: Transfer to tertiary centre for further management or cpap, no 
presponse to therapy within 48-72 hours, pulmonary abscess, empyema, osteomyelitis/septic arthritis, 
necrotizing pneumonia. 
Follow up: 
Hospital follow up: Drop down boxes for yes, no and no data. 

























BTS Paediatric Pneumonia Audk Tool Patient Data Collection Shoot pago 2 
St<:rioN 5.A.lfflaOncs 
5.1 Anti>iotic:s 5.2 Route IVK)ral 
Tldt aU pn1scribed : IV Cnl 
Amclitya..n - ----- -- ----.0 .......................... 0 ....... 0 
Augnenr1 -------- -----.0 .......................... 0 ....... 0 
,,en-------- ----.0 .......................... 0 ....... 0 
----- ---- ----.0 .......................... 0 ....... 0 
eellrotme ------- -----.0 ......................... . 0 ....... 0 
eeptedof --------- -----.0 .......................... 0 ....... 0 
ctarltrom)m ------- ----.0 .......................... 0 ....... 0 
Eryt1IO'll)'Cn - - -- - - - - -- -.0 .......................... 0 ....... 0 
1--'1 -------- ----.0 .......................... 0 ....... 0 
Pel'Q.al - ------- --- -- -- .0 .......................... 0 ....... 0 
011&' --- --------- -----.0 .......................... 0 ....... 0 
6.1• fnl)yana ........ "l\!s 0 ............ Moo ............ .. 
6.2' wngAbce~ ...... "l\!s D ............ NoD ............ .. 
6 .3' Osteomyel ilis / Septic Arthritis 




6A Olhercomplication (ila,s,.'8'ed C,,8' in 6.3)._ __________ __, 
u CtHnolbiditias ..... "l\!s 0 ........... . 
6.5.t' Asthma ...... "l\!s 0 ............ No U .............. Nodala l n>l 
6.5.2'Cysticfi>rosis "l\!s 0 ............ t\'oO .............. Nodala/ n>t 
6.5.3' lrrmunc>Con-.iromi5e Yes 0 ...... Ho O ............ .. 
6.5.4 00. Clsease (peesespeo.ty) ._ __________ __, 
6.6' 1bspita1 Fo11ow ~ Jnarr,iect 0 ..... Nd fil.rgect D ...... .. 
6.7" OM!st X-Ray at follow-up Yes D ............. No D ....... . 



































APPENDIX 6: Instructions to authors of chosen journal 
 
SAJCH AUTHOR GUIDELINES 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, and will delay publication.  
AUTHORSHIP  
Named authors must consent to publication. Authorship should be based on substantial 
contribution to: (i) conception, design, analysis and interpretation of data; (ii) drafting or critical 
revision for important intellectual content; and (iii) approval of the version to be published. 
These conditions must all be met (uniform requirements for manuscripts submitted to biomedical 
journals; refer to www.icmje.org).  
CONFLICT OF INTEREST  
Authors must declare all sources of support for the research and any association with a product 
or subject that may constitute conflict of interest. 
RESEARCH ETHICS COMMITTEE APPROVAL  
Provide evidence of Research Ethics Committee approval of the research where relevant.  
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY  
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or parent or 
guardian) gives informed written consent for publication. The patient should be shown the 
manuscript to be published. Refer to www.icmje.org.  
ETHNIC CLASSIFICATION  
References to ethnic classification must indicate the rationale for this.  
MANUSCRIPTS  
Shorter items are more likely to be accepted for publication, owing to space constraints and 
reader preferences. Original articles not exceeding 3 000 words, with up to 6 tables or 
illustrations, are usually observations or research of relevance to child health. References should 
preferably be limited to no more than 15.  
Please provide a structured abstract not exceeding 250 words, with the following recommended 
headings: Background, Objectives, Methods, Results, and Conclusion.  
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Scientific letters/short reports, which include case reports, side effects of drugs and brief or 
negative research findings should preferably be 1500 words or less, with 1 table or illustration 
and no more than 6 references. Please provide an accompanying abstract not exceeding 150 
words.  
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, will 
be subjected to the SAJCH peer review process. Review articles are rarely accepted unless 
invited. Letters to the editor, for publication, should be about 400 words with only one 
illustration or table, and must include a correspondence address. 
Obituaries should be about 400 words and may be accompanied by a photograph.  
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in doubt, 
refer to 'uniform requirements' - www.icmje.org.  
Manuscripts must be provided in UK English. Qualification, affiliation and contact details of 
ALL authors must be provided in the manuscript and in the online submission process.  
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. Scientific measurements must be expressed 
in SI units except: blood pressure (mmHg) and haemoglobin (g/dl). Litres is denoted with a 
lowercase 'l' e.g. 'ml' for millilitres). Units should be preceded by a space (except for %), e.g. '40 
kg' and '20 cm' but '50%'. Greater/smaller than signs (> and 40 years of age'. The same applies to 
± and º, i.e. '35±6' and '19ºC'. Numbers should be written as grouped per thousand-units, i.e. 4 
000, 22 160...  
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...'  
Round brackets (parentheses) should be used, as opposed to square brackets, which are reserved 
for denoting concentrations or insertions in direct quotes.  
General formatting 
The manuscript must be in Microsoft Word or RTF document format. Text must be single-
spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as text 
in boxes, with the exception of Tables).  
ILLUSTRATIONS AND TABLES  
If tables or illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. Tables may be embedded in the 
manuscript file or provided as 'supplementary files'. They must be numbered in Arabic numerals 
(1,2,3...) and referred to consecutively in the text (e.g. 'Table 1'). Tables should be constructed 
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carefully and simply for intelligible data representation. Unnecessarily complicated tables are 
strongly discouraged. Tables must be cell-based (i.e. not constructed with text boxes or tabs), and 
accompanied by a concise title and column headings. Footnotes must be indicated with 
consecutive use of the following symbols: * † ‡ § ¶ || then ** †† ‡‡ etc.  
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. Figure 
legends: Fig. 1. 'Title...' All illustrations/figures/graphs must be of high resolution/quality: 300 
dpi or more is preferable but images must not be resized to increase resolution. Unformatted and 
uncompressed images must be attached as 'supplementary files' upon submission (not embedded 
in the accompanying manuscript). TIFF and PNG formats are preferable; JPEG and PDF formats 
are accepted, but authors must be wary of image compression. Illustrations and graphs prepared 
in Microsoft Powerpoint or Excel must be accompanied by the original workbook.  
 
REFERENCES 
Authors must verify references from the original sources. Only complete, correctly formatted 
reference lists will be accepted. Reference lists must be generated manually and not with the use 
of reference manager software. Citations should be inserted in the text as superscript numbers 
between square brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6]  
All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). Approved abbreviations of journal titles must be used; 
see the List of Journals in Index Medicus.  
Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. First and last page, volume and issue numbers 
should be given.  
Wherever possible, references must be accompanied by a digital object identifier (DOI) link and 
PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are encouraged to use the DOI 
lookup service offered by CrossRef.  
Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 
2764753]  
Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-
101. Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA jun, Sodeman WA, eds. Pathologic Physiology: Mechanisms 
of Disease. Philadelphia: WB Saunders, 1974:457-472.  
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Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010).  
Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher place: 
publisher name, year; pages.  
Cited manuscripts that have been accepted but not yet published can be included as references 
followed by '(in press)'.  
Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal communications 
e.g. '...(Prof. Michael Jones, personal communication)'. 
PROOFS  
A PDF proof of an article may be sent to the corresponding author before publication to resolve 
remaining queries. At that stage, only typographical changes are permitted; the corresponding 
author is required, having conferred with his/her co-authors, to reply within 2 working days in 
order for the article to be published in the issue for which it has been scheduled.  
CHANGES OF ADDRESS  
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. CPD POINTS Authors can earn up to 15 CPD CEUs for published 
articles. Certificates may be requested after publication of the article. CHARGES There is no 













Submission Preparation Checklist 
• As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors 
that do not adhere to these guidelines. 
• Named authors consent to publication and meet the requirements of authorship as set out 
by the journal. 
• The submission has not been previously published, nor is it before another journal for 
consideration. 
• The text complies with the stylistic and bibliographic requirements in Author Guidelines. 
• The manuscript is in Microsoft Word or RTF document format. The text is single-spaced, 
in 12-point Times New Roman font, and contains no unnecessary formatting. 
• Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (preferably TIFF or PNG). These must be submitted as 'supplementary files' (not 
in the manuscript). 
• For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
• Where possible, references are accompanied by a digital object identifier (DOI) and 
PubMed ID (PMID)/PubMed Central ID (PMCID). 
• An abstract has been included where applicable. 
• The research was approved by a Research Ethics Committee (if applicable) 
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